PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies

被引：0

作者：

Diab, A. ^{[1
]}

Hurwitz, M. E. ^{[2
]}

Tannir, N. ^{[3
]}

Bernatchez, C. ^{[1
]}

Haymaker, C. ^{[1
]}

Bentebibel, S. E. ^{[1
]}

Curti, B. D. ^{[4
,5
]}

Wong, M. K. K. ^{[1
]}

Gergel, I. ^{[6
]}

Tagliaferri, M. ^{[7
]}

Zalevsky, J. ^{[8
]}

Hoch, U. ^{[9
]}

Aung, S. ^{[7
]}

Imperiale, M. ^{[7
]}

Cho, D. ^{[10
]}

Tykodi, S. S. ^{[11
,12
]}

Puzanov, I. ^{[13
]}

Kluger, H. ^{[14
]}

Hwu, P. ^{[1
]}

Sznol, M. ^{[15
]}

机构：

[1] MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX USA

[2] Yale Sch Med, Div Med Oncol, Dept Internal Med, New Haven, CT USA

[3] MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX USA

[4] Providence Canc Ctr, Dept Genitourinary Oncol Res, Portland, OR USA

[5] Earle A Chiles Res Inst, Portland, OR USA

[6] Nektar Therapeut, Dept Drug Dev, San Francisco, CA USA

[7] Nektar Therapeut, Dept Clin Dev, San Francisco, CA USA

[8] Nektar Therapeut, Dept Biol & Preclin Dev, San Francisco, CA USA

[9] Nektar Therapeut, Dept Clin Pharmacol, San Francisco, CA USA

[10] Dept Med Oncol, NYU Med Oncol Associates, New York, NY USA

[11] Univ Washington, Dept Med Oncol, Seattle, WA 98195 USA

[12] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[13] Roswell Pk Canc Inst, Dept Med Oncol, Buffalo, NY 14263 USA

[14] Yale Breast Ctr, Dept Med Oncol, New Haven, CT USA

[15] Yale Univ, Dept Med Oncol, Sch Med Med Oncol, New Haven, CT USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1212TiP

引用

页数：2

共 50 条

[21] IL believe: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon IL-2 ß/γ alone or in combination with pembrolizumab or standard-of-care chemotherapy in patients with locally advanced or metastatic solid tumors
Starodub, Alexander
Gabrail, Nashat Y.
Zhang, Ying
Castro, Davis Y. Torrejon
Slavsky, Sibel
Singel, Stina Mui
Powderly, John D.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[22] A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors
Keam, B.
Ahn, J-H.
Kim, K.
Hong, S-H.
Ganju, V.
Lim, L. E.
Kwatra, V.
Body, A.
Rhee, P. D.
Jung, S.
Yoon, J.
Baek, E.
Noh, Y. S.
ANNALS OF ONCOLOGY, 2024, 35 : S532 - S532
[23] Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
El-Khoueiry, Anthony B.
Sangro, Bruno
Yau, Thomas
Crocenzi, Todd S.
Kudo, Masatoshi
Hsu, Chiun
Kim, Tae-You
Choo, Su-Pin
Trojan, Jorg
Welling, Theodore H., III
Meyer, Tim
Kang, Yoon-Koo
Yeo, Winnie
Chopra, Akhil
Anderson, Jeffrey
dela Cruz, Christine
Lang, Lixin
Neely, Jaclyn
Tang, Hao
Dastani, Homa B.
Melero, Ignacio
LANCET, 2017, 389 (10088): : 2492 - 2502
[24] Vorolanib (CM082) in Chinese patients with advanced solid tumor: A phase 1, open-label, dose escalation study.
Song, Yan
Wang, Jinwan
Zhou, Ai-Ping
Zhang, Wen
Liang, Chris
Yang, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[25] transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors.
Davar, Diwakar
Singel, Stina M.
Nyamuswa, Gil
Tuan-Anh Tran
Wu, Yang
Grewal, Jaspreet
Aghmesheh, Morteza
Spira, Alexander
Ganju, Vinod
Rand, Jamie
Frentzas, Sophia
Bajor, David
Gabrail, Nashat
CANCER RESEARCH, 2022, 82 (12)
[26] A phase 1, open-label, dose escalation study of AMG 337 in Asian patients (pts) with advanced solid tumors
Yasui, Hirofumi
Amore, Benny
Jiang, Yizhou
Murugappan, Swaminathan
Doi, Toshihiko
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[27] NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Choo, J.
Jeraj, S. Nathan
Chan, G.
Sundar, R.
Yong, W. P.
Lee, M.
Ngoi, N. Y. L.
Wong, A.
Soo, R. A.
Chee, C. E.
Lim, J.
Goh, B-C.
Lee, S. C.
Tan, D. S.
ANNALS OF ONCOLOGY, 2023, 34 : S1498 - S1498
[28] PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC)
Huddart, Robert A.
Siefker-Radtke, Arlene O.
Balar, Arjun Vasant
Bilen, Mehmet Asim
Powles, Thomas
Bamias, Aristotelis
Castellano, Daniel
Khalil, Maged F.
Van der Heijden, Michiel Simon
Koshkin, Vadim S.
Pook, David William
Ozguroglu, Mustafa
Santiago, Linda
Saab, Rabih
Li, Pao-Chen
Tagliaferri, Margit Cecile
Lin, Wei
Tagliaferri, Mary Ann
Loriot, Yohann
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[29] A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
Diab, Adi
Hamid, Omid
Thompson, John A.
Ros, Willeke
Eskens, Ferry A. L. M.
Doi, Toshihiko
Hu-Lieskovan, Siwen
Klempner, Samuel J.
Ganguly, Bishu
Fleener, Catherine
Wang, Xiao
Joh, Tenshang
Liao, Ken
Salek-Ardakani, Shahram
Taylor, Carrie Turich
Chou, Jeffrey
El-Khoueiry, Anthony B.
CLINICAL CANCER RESEARCH, 2022, 28 (01) : 71 - 83
[30] Open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707 as a single agent and in combination with a PD-1 inhibitor in adult subjects with advanced or metastatic solid tumors
Luo, David
Abdul-Karim, Raghad
Azad, Arun
Bendell, Joanna
Gan, Hui
Janku, Filip
Sen, Shiraj
Tan, Tira
Wang, Judy
Schechet, Lisa
Baker, Lauren
Leveque, Joseph
Meniawy, Tarek
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

← 1 2 3 4 5 →